Trial Profile
A Phase 1/2a Exploratory Clinical Trial: Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Tirofiban (Primary)
- Indications Subarachnoid haemorrhage
- Focus Adverse reactions; Therapeutic Use
- Acronyms iSPASM
- Sponsors Medicure
- 07 Sep 2021 Status changed from active, no longer recruiting to completed.
- 02 Sep 2021 Primary endpoint (Analysis of adverse events or death related to tirofiban, compared by a 2-sided 2 test with a 0.05 type I error rate) has not been met according to the results published in the Stroke
- 02 Sep 2021 Primary endpoint (Asymptomatic Hemorrhage) has not been met according to the results published in the Stroke